



ImpediMed Limited
1/50 Parker Court,
Pinkenba, QLD, 4008
Australia

14 February 2024

Companies Announcements Office
Australian Securities Exchange

New Multinational Clinical Practice Guidance Recommends Use of BIS

Key Points

- Leading medical journal *eClinicalMedicine*, part of *The Lancet Discovery Science* has published Multinational Association of Supportive Care in Cancer (MASCC) guidelines which specifically include bioimpedance spectroscopy (BIS) as a recommended option to identify early signs of lymphoedema.
- The MASCC guidance was generated by a global panel, including participants from Japan, USA, Hong Kong, Canada, Italy, Denmark, Australia, Spain and UK. These recommendations support ImpediMed's US and global sales efforts. SOZO is available in the US, Australia, New Zealand, Hong Kong, UK, Ireland, Denmark and Sweden.
- BIS for prevention of breast cancer-related lymphoedema is now included in the globally referenced NCCN Guidelines and MASCC Guidelines.
- SOZO is the only FDA cleared and clinically validated BIS system for the early detection and monitoring of lymphoedema.

The Multinational Association of Supportive Care in Cancer is a global professional organisation dedicated to improving the lives of people with cancer and their families by advancing supportive care research, education, and clinical practice. The MASCC guidance specifically names bioimpedance spectroscopy as a recommended option to identify early signs of lymphoedema along with specific thresholds for ImpediMed's L-Dex®.

ImpediMed has the only FDA-cleared BIS technology for the assessment of lymphoedema. The Company's SOZO® Digital Health Platform is broadly accepted and recognised for effective and accurate screening of lymphoedema.

A link to the full manuscript in *The Lancet* is available at [https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370\(24\)00020-8/fulltext](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00020-8/fulltext).

Approved for release by Managing Director and CEO, Dr. Parmjot Bains.

For more information, contact Dr Parmjot Bains MD/Interim CEO or McGregor Grant Interim CFO on +61 7 3860 3700 or email investorrelations@impedimed.com.

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximize patient health. ImpediMed produces the SOZO[®] Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines[®]) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex[®], ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.

About the PREVENT Trial

The PREVENT trial is a pivotal study, the largest randomised controlled trial to assess lymphoedema prevention. This international, multi-institutional randomised controlled trial provided level I evidence demonstrating that intervention in patients with early detection of cancer-related lymphoedema using ImpediMed's L-Dex[®] technology resulted in a lower rate of progression to chronic disease than patients with early detection from volume measurements using a tape measure. The statistically significant results demonstrated that bioimpedance spectroscopy (BIS) screening should be a standard approach for prospective breast cancer-related lymphoedema (BCRL) surveillance. The trial followed over 1,200 patients for three years across 13 medical centers across the US and Australia. Patients enrolled in the study included breast cancer survivors whose treatment puts them at risk for developing secondary, chronic lymphoedema in one of their arms. These patients were randomised to follow up monitoring for lymphoedema development using either L-Dex or tape measure-based volume measurements.

About SOZO Digital Health Platform

SOZO, the world's most advanced, non-invasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphoedema, provides fluid status for patients living with heart or renal failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: <https://www.impedimed.com/products/sozo/>.